Alexion Pharmaceuticals investors were celebrating last week when word on the street said Amgen might buy out the company, but a week later, their mood is much different. The buyout hope was dashed Monday when Amgen announced it would buy Celgene’s Otezla, and now the U.S. Patent and Trademark Office (PTO) has struck up a review of… Read More »
Editorial pages weigh in on a range of public health topics stemming from gun violence. The Wall Street Journal: Guns And The Do-Something Fallacy “Do something!” someone shouted at Ohio Gov. Mike DeWine. The shout came during a candlelight vigil in downtown Dayton, where a disturbed young man just hours before had shot to death… Read More »
Dive Brief: The leaders of the Senate HELP Committee on Thursday proposed a wide-ranging and ambitious package of healthcare bills, including measures addressing surprise medical billing, price transparency, interoperability, drug costs and public health. One bill put forward would require commercial insurers to make claims data and expected out-of-pocket costs available to patients through application… Read More »
Back in November, Pfizer and Merck KGaA reported that immuno-oncology drug Bavencio had failed a late-stage ovarian cancer trial. And now the companies can make it two. Friday, the partners said they’d scrapped a phase 3 study examining Bavencio in combination with and/or after chemo in previously untreated patients after the drug showed it couldn’t… Read More »
The pharmaceutical industry has done it for years, officially to educate doctors, unofficially to convince them to prescribe more of their medicines. Now the practice of company-sponsored seminars by specialists known in the drug business as “key opinion leaders” — and criticized as salespeople in disguise – has come to the burgeoning world of medical… Read More »